I will stop short of telling you which to buy, I will try to help make your decision less stressful. They both are cell therapy companies with no FDA approved therapy (yet). One of them gets their cells processed by another company, and the other one owns a Contract Manufacturing company that not only manufactures cell therapies for itself but also manufactures therapies for other companies including Baxter, Dendreon, and IMUC. I am VERY long NBS.
Sentiment: Strong Buy
yeah...but as Neii wrote: ATHX is kinda "big deal" somehow. Something in back of my brain tells me it can be bigger that NBS if it works...damn it. That is why i don't know whom to cut. ATHX multistem platform is crazy. If it works of course. NBS on other hand produces something allready... Well i will keep both i guess.
I have both. If ATHX's platform works, it's clearly better. But NBS released great results for phase 1 AMR-001 then did ATHX did post phase 1 results for its IBD product. Cannot draw conclusions on such limited information, but can difintively conclude NBS has revenue from services whereas ATHX is dependent on their Pfizer deal. If ATHX fails their phase 2, it's going to .25 cents a share.